IDEAS home Printed from https://ideas.repec.org/f/pga659.html
   My authors  Follow this author

Afschin Gandjour

Personal Details

First Name:Afschin
Middle Name:
Last Name:Gandjour
Suffix:
RePEc Short-ID:pga659
[This author has chosen not to make the email address public]
http://www.fs.de/gandjour

Affiliation

Frankfurt School of Finance and Management

Frankfurt, Germany
http://www.frankfurt-school.de/
RePEc:edi:hfbfide (more details at EDIRC)

Research output

as
Jump to: Articles

Articles

  1. Afschin Gandjour, 2012. "Presenting Germany’s drug pricing rule as a cost-per-QALY rule," Health Care Management Science, Springer, vol. 15(2), pages 103-107, June.
  2. Gandjour, Afschin & Chernyak, Nadja, 2011. "A new prize system for drug innovation," Health Policy, Elsevier, vol. 102(2), pages 170-177.
  3. Gandjour, Afschin & Gafni, Amiram, 2010. "The additive utility assumption of the QALY model revisited," Journal of Health Economics, Elsevier, vol. 29(2), pages 325-328, March.
  4. Afschin Gandjour, 2008. "Mutual dependency between capabilities and functionings in Amartya Sen’s capability approach," Social Choice and Welfare, Springer;The Society for Social Choice and Welfare, vol. 31(2), pages 345-350, August.
  5. Gandjour, Afschin & Stock, Stephanie, 2007. "A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness," Health Policy, Elsevier, vol. 83(2-3), pages 257-267, October.
  6. Afschin Gandjour, 2006. "Consumption costs and earnings during added years of life ‐ a reply to Nyman," Health Economics, John Wiley & Sons, Ltd., vol. 15(3), pages 315-317, March.
  7. Afschin Gandjour & Eva-Julia Weyler, 2006. "Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries," Health Care Management Science, Springer, vol. 9(4), pages 359-369, November.
  8. Gandjour, Afschin & Lauterbach, Karl Wilhelm, 2005. "Does prevention save costs?: Considering deferral of the expensive last year of life," Journal of Health Economics, Elsevier, vol. 24(4), pages 715-724, July.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Articles

  1. Afschin Gandjour, 2012. "Presenting Germany’s drug pricing rule as a cost-per-QALY rule," Health Care Management Science, Springer, vol. 15(2), pages 103-107, June.

    Cited by:

    1. Afschin Gandjour, 2015. "Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”," PharmacoEconomics, Springer, vol. 33(9), pages 981-982, September.
    2. Afschin Gandjour, 2015. "Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule," International Journal of Health Planning and Management, Wiley Blackwell, vol. 30(4), pages 395-402, October.

  2. Gandjour, Afschin & Chernyak, Nadja, 2011. "A new prize system for drug innovation," Health Policy, Elsevier, vol. 102(2), pages 170-177.

    Cited by:

    1. Armin Mertens & Marc Scheufen, 2024. "Intellectual property and fourth industrial revolution technologies: how the patent system is shaping the future in the data-driven economy," European Journal of Law and Economics, Springer, vol. 57(1), pages 275-310, April.
    2. Skliaustyte, Egle & Weber, Matthias, 2021. "Subsidies or Tax Breaks Versus Intellectual Property Rights: Dual Markets," SocArXiv x87fy, Center for Open Science.

  3. Gandjour, Afschin & Gafni, Amiram, 2010. "The additive utility assumption of the QALY model revisited," Journal of Health Economics, Elsevier, vol. 29(2), pages 325-328, March.

    Cited by:

    1. Edouard Kujawski & Evangelos Triantaphyllou & Juri Yanase, 2019. "Additive Multicriteria Decision Analysis Models: Misleading Aids for Life-Critical Shared Decision Making," Medical Decision Making, , vol. 39(4), pages 437-449, May.

  4. Afschin Gandjour, 2008. "Mutual dependency between capabilities and functionings in Amartya Sen’s capability approach," Social Choice and Welfare, Springer;The Society for Social Choice and Welfare, vol. 31(2), pages 345-350, August.

    Cited by:

    1. Farah Naz, 2022. "Capabilities and Human Well-Being: How to Bridge the Missing Link?," International Journal of Innovation and Economic Development, Inovatus Services Ltd., vol. 8(2), pages 61-71, June.
    2. Roberta Sferrazzo & Renato Ruffini, 2021. "Are Liberated Companies a Concrete Application of Sen’s Capability Approach?," Journal of Business Ethics, Springer, vol. 170(2), pages 329-342, May.
    3. Leon, Dorian, 2017. "Enfoque de capacidades: una introducción formal [Capability approach: a formal introduction]," MPRA Paper 79877, University Library of Munich, Germany, revised 24 Jun 2017.
    4. Dorian Fernando LEON, 2017. "Capability Approach: A Formal Introduction," Journal of Economics and Political Economy, KSP Journals, vol. 4(2), pages 215-218, June.
    5. León Tamayo, Dorian Fernando, 2017. "Enfoque de capacidades: una introducción formal [Capability approach: a formal introduction]," MPRA Paper 79879, University Library of Munich, Germany, revised 25 Jun 2017.

  5. Gandjour, Afschin & Stock, Stephanie, 2007. "A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness," Health Policy, Elsevier, vol. 83(2-3), pages 257-267, October.

    Cited by:

    1. Robert L. Herrick & Steven G. Buchberger & Robert M. Clark & Margaret Kupferle & Regan Murray & Paul Succop, 2012. "A Markov Model To Estimate Salmonella Morbidity, Mortality, Illness Duration, And Cost," Health Economics, John Wiley & Sons, Ltd., vol. 21(10), pages 1169-1182, October.
    2. Dirk Mueller & Afschin Gandjour, 2008. "Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women," Applied Health Economics and Health Policy, Springer, vol. 6(2), pages 113-135, July.
    3. Rachel A. Elliott & Lukasz Tanajewski & Georgios Gkountouras & Anthony J. Avery & Nick Barber & Rajnikant Mehta & Matthew J. Boyd & Asam Latif & Antony Chuter & Justin Waring, 2017. "Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal," PharmacoEconomics, Springer, vol. 35(12), pages 1237-1255, December.
    4. Eberhard Wille & Jürgen Scholze & Eduardo Alegria & Claudio Ferri & Sue Langham & Warren Stevens & David Jeffries & Kerstin Uhl-Hochgraeber, 2011. "Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 205-218, June.
    5. Afschin Gandjour, 2010. "A model to predict the cost‐effectiveness of disease management programs," Health Economics, John Wiley & Sons, Ltd., vol. 19(6), pages 697-715, June.
    6. Dirk Mueller & Eva Weyler & Afschin Gandjour, 2008. "Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis," PharmacoEconomics, Springer, vol. 26(6), pages 513-536, June.
    7. Daniel M. Sugrue & Thomas Ward & Sukhvir Rai & Phil McEwan & Heleen G. M. Haalen, 2019. "Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design," PharmacoEconomics, Springer, vol. 37(12), pages 1451-1468, December.
    8. Dirk Mueller & Afschin Gandjour, 2011. "Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis," Applied Health Economics and Health Policy, Springer, vol. 9(4), pages 259-273, July.

  6. Afschin Gandjour, 2006. "Consumption costs and earnings during added years of life ‐ a reply to Nyman," Health Economics, John Wiley & Sons, Ltd., vol. 15(3), pages 315-317, March.

    Cited by:

    1. Linda M. Vries & Pieter H. M. Baal & Werner B. F. Brouwer, 2019. "Future Costs in Cost-Effectiveness Analyses: Past, Present, Future," PharmacoEconomics, Springer, vol. 37(2), pages 119-130, February.
    2. Bengt Liljas, 2011. "Welfare, QALYs, and costs – a comment," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 68-72, January.
    3. Douglas Lundin & Joakim Ramsberg, 2008. "On survival consumption costs – a reply to Nyman," Health Economics, John Wiley & Sons, Ltd., vol. 17(2), pages 293-297, February.
    4. Erik Nord & Christoffer Lamøy, 2018. "Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary," PharmacoEconomics - Open, Springer, vol. 2(4), pages 357-358, December.
    5. John A. Nyman, 2011. "Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 56-67, January.
    6. Afschin Gandjour & Dirk Müller, 2014. "Ethical Objections Against Including Life-Extension Costs in Cost-Effectiveness Analysis: A Consistent Approach," Applied Health Economics and Health Policy, Springer, vol. 12(5), pages 471-476, October.
    7. Bengt Liljas & Göran S. Karlsson & Nils‐Olov Stålhammar, 2008. "On future non‐medical costs in economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 17(5), pages 579-591, May.
    8. Liqun Liu & Andrew J. Rettenmaier & Thomas R. Saving, 2012. "Endogenous Patient Responses and the Consistency Principle in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 32(3), pages 488-497, May.
    9. Marie Kruse & Jan Sørensen & Dorte Gyrd-Hansen, 2012. "Future costs in cost-effectiveness analysis: an empirical assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 63-70, February.
    10. Charles Christian Adarkwah & Amirhossein Sadoghi & Afschin Gandjour, 2016. "Should Cost‐Effectiveness Analysis Include the Cost of Consumption Activities? AN Empirical Investigation," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 249-256, February.
    11. Matthijs Versteegh & Saskia Knies & Werner Brouwer, 2016. "From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare," PharmacoEconomics, Springer, vol. 34(11), pages 1071-1074, November.
    12. Daniel Grima & Lisa Bernard & Elizabeth Dunn & Philip McFarlane & David Mendelssohn, 2012. "Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis," PharmacoEconomics, Springer, vol. 30(11), pages 981-989, November.
    13. Afschin Gandjour, 2021. "How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany," Applied Health Economics and Health Policy, Springer, vol. 19(2), pages 181-190, March.

  7. Afschin Gandjour & Eva-Julia Weyler, 2006. "Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries," Health Care Management Science, Springer, vol. 9(4), pages 359-369, November.

    Cited by:

    1. Dirk Mueller & Afschin Gandjour, 2008. "Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women," Applied Health Economics and Health Policy, Springer, vol. 6(2), pages 113-135, July.
    2. Dirk Mueller & Eva Weyler & Afschin Gandjour, 2008. "Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis," PharmacoEconomics, Springer, vol. 26(6), pages 513-536, June.
    3. Douglas Wolf & Thomas Gill, 2009. "Modeling transition rates using panel current-status data: How serious is the bias?," Demography, Springer;Population Association of America (PAA), vol. 46(2), pages 371-386, May.
    4. Dirk Mueller & Afschin Gandjour, 2011. "Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis," Applied Health Economics and Health Policy, Springer, vol. 9(4), pages 259-273, July.

  8. Gandjour, Afschin & Lauterbach, Karl Wilhelm, 2005. "Does prevention save costs?: Considering deferral of the expensive last year of life," Journal of Health Economics, Elsevier, vol. 24(4), pages 715-724, July.

    Cited by:

    1. Linda M. Vries & Pieter H. M. Baal & Werner B. F. Brouwer, 2019. "Future Costs in Cost-Effectiveness Analyses: Past, Present, Future," PharmacoEconomics, Springer, vol. 37(2), pages 119-130, February.
    2. Albert Wong & Pieter H. M. van Baal & Hendriek C. Boshuizen & Johan J. Polder, 2011. "Exploring the influence of proximity to death on disease‐specific hospital expenditures: a carpaccio of red herrings," Health Economics, John Wiley & Sons, Ltd., vol. 20(4), pages 379-400, April.
    3. Pieter H. M. van Baal & Talitha L. Feenstra & Rudolf T. Hoogenveen & G. Ardine de Wit & Werner B. F. Brouwer, 2007. "Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’ cost–utility ratio," Health Economics, John Wiley & Sons, Ltd., vol. 16(4), pages 421-433, April.
    4. Afschin Gandjour & Eva-Julia Weyler, 2006. "Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries," Health Care Management Science, Springer, vol. 9(4), pages 359-369, November.
    5. van Baal, P.H. & Feenstra, T.L. & Polder, J.J. & Hoogenveen, R.T. & Brouwer, W., 2011. "Economic evaluation and the postponement of health care costs," Other publications TiSEM ee3d1a20-234a-46d7-8acd-d, Tilburg University, School of Economics and Management.
    6. Hamraz Mokri & Ingelin Kvamme & Linda Vries & Matthijs Versteegh & Pieter Baal, 2023. "Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 701-715, July.
    7. Emi Sato & Kiyohide Fushimi, 2009. "What has influenced patient health‐care expenditures in Japan?: variables of age, death, length of stay, and medical care," Health Economics, John Wiley & Sons, Ltd., vol. 18(7), pages 843-853, July.
    8. Dieter Tscheulin & Florian Drevs, 2010. "The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 141-150, April.
    9. Maria Gheorghe & Werner B. F. Brouwer & Pieter H. M. van Baal, 2015. "Quality of Life and Time to Death," Medical Decision Making, , vol. 35(3), pages 316-327, April.
    10. Astrid Ledgaard Holm & Lennert Veerman & Linda Cobiac & Ola Ekholm & Finn Diderichsen, 2014. "Cost-Effectiveness of Preventive Interventions to Reduce Alcohol Consumption in Denmark," PLOS ONE, Public Library of Science, vol. 9(2), pages 1-9, February.
    11. Afschin Gandjour, 2009. "Aging diseases – do they prevent preventive health care from saving costs?," Health Economics, John Wiley & Sons, Ltd., vol. 18(3), pages 355-362, March.
    12. Patrick Moore & Kathleen Bennett & Charles Normand, 2014. "The Importance of Proximity to Death in Modelling Community Medication Expenditures for Older People: Evidence From New Zealand," Applied Health Economics and Health Policy, Springer, vol. 12(6), pages 623-633, December.
    13. Meliyanni Johar, 2017. "The Evolution of Out-of-Hospital Medical Costs to and through Retirement," Economic Papers, The Economic Society of Australia, vol. 36(1), pages 17-31, March.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Afschin Gandjour should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.